The role of antioxidants in the era of cardio-oncology Duncan T. VincentYasmine F. IbrahimYuichiro J. Suzuki Review Article 20 August 2013 Pages: 1157 - 1168
The VEGF pathway in lung cancer Michalis AlevizakosSerafim KaltsasKonstantinos N. Syrigos Review Article 02 October 2013 Pages: 1169 - 1181
Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis Guilhem BousquetMariana VarnaAnne Janin Original Article 24 September 2013 Pages: 1183 - 1193
Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice Robert A. PariseJan H. BeumerJulie L. Eiseman Original Article 24 September 2013 Pages: 1195 - 1204
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study Rachel C. JankowitzJame AbrahamSamuel A. Jacobs Original Article 29 September 2013 Pages: 1205 - 1212
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors L. Rhoda MolifeSarah M. RudmanJames Spicer Original Article 02 October 2013 Pages: 1213 - 1222
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers Catherine DutreixFlorence MunariniYanfeng Wang Original Article Open access 02 October 2013 Pages: 1223 - 1234
Angiotensin-(1–7) synergizes with colony-stimulating factors in hematopoietic recovery Kathleen E. RodgersTheresa B. EspinozaGere S. diZerega Original Article 05 October 2013 Pages: 1235 - 1245
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401 In-Jae OhKyu-Sik KimSung-Ja Ahn Original Article 05 October 2013 Pages: 1247 - 1254
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase Santhosh PalaniMayankbhai PatelArijit Chakravarty Original Article 08 October 2013 Pages: 1255 - 1264
Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases Sean S. GarciaJohnique T. AtkinsRazelle Kurzrock Original Article 08 October 2013 Pages: 1265 - 1271
13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients Geraldo FelĂcio Cunha-JuniorLuiz De MarcoLuiz Gonzaga Coelho Original Article 08 October 2013 Pages: 1273 - 1282
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy Toru KonoTaishi HataHideyuki Mishima Original Article Open access 12 October 2013 Pages: 1283 - 1290
A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer Yousuke NakaiHiroyuki IsayamaKazuhiko Koike Original Article 12 October 2013 Pages: 1291 - 1297
Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics Kohei MotoshimaYoichi NakamuraShigeru Kohno Original Article 12 October 2013 Pages: 1299 - 1304
Phase 1 study of N 1,N 11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma Lipika GoyalJeffrey G. SupkoAndrew X. Zhu Original Article 12 October 2013 Pages: 1305 - 1314
A novel antitumor piperazine alkyl compound causes apoptosis by inducing RhoB expression via ROS-mediated c-Abl/p38 MAPK signaling Kyung-Sook ChungGyoonhee HanMisun Won Original Article 13 October 2013 Pages: 1315 - 1324
Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period Shogo KobayashiHiroshi WadaHiroaki Nagano Original Article 13 October 2013 Pages: 1325 - 1333
Flow cytometric chemosensitivity assay using JC-1, a sensor of mitochondrial transmembrane potential, in acute leukemia Tomoko YokosukaHiroaki GotoShumpei Yokota Original Article 13 October 2013 Pages: 1335 - 1342
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours Laura HorsleyJeff CummingsA Cancer Research UK Drug Development Office Phase I clinical trial Clinical Trial Report 20 October 2013 Pages: 1343 - 1352
Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401 Koichi TakayamaKoji InoueYoichi Nakanishi Clinical Trial Report 29 October 2013 Pages: 1353 - 1359
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs Vincent Launay-Vacher Short Communication 22 September 2013 Pages: 1361 - 1367
Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients Tamer A. AhmedJohn HayslipMarkos Leggas Short Communication 27 October 2013 Pages: 1369 - 1374
Erratum to: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments Jennifer L. PauleyJohn C. PanettaMary V. Relling Erratum 29 October 2013 Pages: 1375 - 1375